Teleflex (NYSE:TFX – Get Free Report) and Vasamed (OTCMKTS:VSMD – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.
Valuation and Earnings
This table compares Teleflex and Vasamed”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Teleflex | $1.99 billion | 2.99 | -$905.64 million | ($23.29) | -6.04 |
| Vasamed | N/A | N/A | N/A | N/A | N/A |
Institutional & Insider Ownership
95.6% of Teleflex shares are held by institutional investors. 0.7% of Teleflex shares are held by company insiders. Comparatively, 8.0% of Vasamed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Teleflex and Vasamed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Teleflex | -39.67% | 11.93% | 5.44% |
| Vasamed | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Teleflex and Vasamed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Teleflex | 1 | 6 | 4 | 1 | 2.42 |
| Vasamed | 0 | 0 | 0 | 0 | 0.00 |
Teleflex presently has a consensus price target of $152.90, suggesting a potential upside of 8.76%. Given Teleflex’s stronger consensus rating and higher probable upside, research analysts plainly believe Teleflex is more favorable than Vasamed.
Summary
Teleflex beats Vasamed on 8 of the 10 factors compared between the two stocks.
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
About Vasamed
Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
